The Latest Cardiac and Vascular News
– Third-quarter sales growth of 5.5 percent; organic sales growth of 7.6 percent – Exceptional growth across key platforms of FreeStyle Libre, MitraClip and Alinity – Continues to strengthen portfolio with a steady cadence of new product approvals, reimbursement coverage […]
– New data presented at TCT 2019 on Abbott’s TriClip device from the TRILUMINATE Feasibility Study met both the primary safety and performance endpoints – Abbott’s TriClip tricuspid valve repair system design is based on the company’s market-leading MitraClip™ technology […]
Newly cleared diagnostic test could help identify heart attacks several hours sooner than standard troponin tests and help improve diagnosis in women ABBOTT PARK, Ill., Sept. 25, 2019 /PRNewswire/ — Abbott (NYSE: ABT) today announced that its ARCHITECT STAT High Sensitivity Troponin-I blood test […]
– World’s smallest pediatric treatments pioneered by Abbott address critical needs for the most vulnerable patients: babies and children born with common congenital heart defects – Includes pediatric mechanical heart valve and first minimally invasive device to treat premature babies […]
New research found Abbott’s algorithm created through machine learning could give doctors a more individualized calculation, leveraging factors such as age, sex and the changing dynamics of troponin protein levels in the blood, to improve heart attack diagnosis This technology […]
– TRILUMINATE Pivotal trial is the world’s first randomized clinical trial to evaluate transcatheter tricuspid valve repair in patients with severe tricuspid regurgitation – There are currently no approved transcatheter tricuspid repair treatments, limiting options for patients with leaky tricuspid […]
ABBOTT PARK, Ill., July 15, 2019 /PRNewswire/ — Abbott (NYSE: ABT) today announced the company has received U.S. Food and Drug Administration (FDA) approval for the most advanced MitraClip™ heart valve repair device to treat mitral regurgitation. The latest approval for the fourth-generation MitraClip […]
PARIS, May 21, 2019 /PRNewswire/ — Abbott (NYSE: ABT) today announced positive late-breaking data from its TRILUMINATE study of the company’s minimally invasive tricuspid valve repair system. Results at 30 days demonstrated that the investigational device is associated with a reduction of tricuspid regurgitation […]
ABBOTT PARK, Ill., May 6, 2019 /PRNewswire/ — Abbott today announced the launch of a new, smarter heart monitor for better arrhythmia detection—positive news for people at risk for irregular heartbeats. Now with CE Mark in Europe and U.S. Food and Drug Administration (FDA) clearance, […]
ABBOTT PARK, Ill., April 29, 2019 /PRNewswire/ — Abbott (NYSE: ABT) announced today that a new study published in Circulation found its High Sensitive Troponin-I blood test could predict the chance of developing a cardiac event years before it occurs in people with no symptoms when […]
